Publications by authors named "Kleinheinz A"
Article Synopsis
- Long-term effectiveness and safety of omalizumab for Chronic Inducible Urticaria (CIndU) were evaluated in a large cohort across 14 specialized centers, revealing it to be highly effective for most patients.
- Out of 234 patients, 73% reported significant improvements while the median treatment duration exceeded 5 years, mainly due to disease control.
- Patient age was a predictor of treatment continuation, with older patients less likely to discontinue due to well-controlled disease, and CIndU subtype did not impact treatment response or duration.
Importance: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences.
View Article and Find Full Text PDFArticle Synopsis
- Eczema herpeticum (EH) is a skin infection from the herpes virus that affects patients with atopic dermatitis (AD), and a study sought to evaluate its prevalence and characteristics in a larger group of patients.* -
- In a study of 893 AD patients, 21.8% experienced at least one episode of EH, with over half of those (54.9%) suffering from multiple episodes.* -
- The findings indicate a high recurrence of EH among AD patients, yet no distinct clinical traits were found to differentiate these patients, apart from an increased number of allergies.*
Background: Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy.
Objective: We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination.
Methods: COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine.
Background: TREATgermany is a multicenter registry including patients with moderate-to-severe atopic dermatitis (AD) from currently 74 study centers (university clinics, hospitals and practices) in Germany. As of August 31, 2021, 1,230 adult patients were enrolled.
Methods: In TREATgermany, patients and physicians fill in questionnaires pertaining to symptoms, disease severity, quality of life, depressiveness, and fatigue.
Background: Atopic dermatitis (AD) patients display an altered skin microbiome which may not only be an indicator but also a driver of inflammation. We aimed to investigate associations among AD patients' skin microbiome, clinical data, and response to systemic therapy in patients of the TREATgermany registry.
Methods: Skin swabs of 157 patients were profiled with 16S rRNA gene amplicon sequencing before and after 3 months of treatment with dupilumab or cyclosporine.
Article Synopsis
- Peanut allergies can be really tough for kids and their caregivers because they often have to avoid peanuts and use medicine if they accidentally eat them.
- A new treatment called Palforzia has been tested in children aged 4 to 17, and it showed that they can eat more peanuts without getting very sick.
- The study measured how much peanut people could eat and how bad their symptoms were, helping doctors and families understand the treatment's effectiveness better.
TREATgermany is an investigator-initiated prospective disease registry. It investigates physician- and patient-reported disease severity (Eczema Area and Severity Index (EASI), objective Scoring Atopic Dermatitis (oSCORAD), Investigator Global Assessment, Patient-Oriented Eczema Measure (POEM), Patient Global Assessment (PGA)), patient-reported symptoms (itch, sleep loss, depressive symptoms), therapy courses and dermatological quality of life (DLQI) in moderate-to-severe atopic dermatitis with SCORAD > 20. 1,134 atopic dermatitis patients (mean age 41.
View Article and Find Full Text PDFThis interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.
View Article and Find Full Text PDFAims: To identify possible histopathological risk factors for malignancy in skin biopsies of dermatomyositis patients.
Methods And Results: We analysed clinical metadata and studied 30 skin biopsies of 11 patients with and 12 patients without associated malignancy, who were treated in one secondary and one tertiary German medical centre between 2009 and 2022 and fulfilling the EULAR/ACR classification criteria for dermatomyositis. Specimens were categorized by malignancy status and evaluated based on haematoxylin and eosin (H&E), periodic acid Schiff (PAS), Alcian Blue, and anti-CD123 immunohistochemistry stains.
Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis.
J Allergy Clin Immunol
August 2022
Background: Few studies have analyzed the blood transcriptome in atopic dermatitis (AD).
Objective: We explored blood transcriptomic features of moderate to severe AD.
Methods: Blood messenger RNA sequencing on 60 adults from the TREATgermany registry including 49 patients before and after dupilumab treatment, as well as from an independent cohort of 31 patients and 43 controls was performed.
Background: TREATgermany, a registry for patients with moderate to severe atopic dermatitis (AD), established an additional questionnaire in spring 2020 to investigate the effects of the coronavirus pandemic on the daily life of patients with AD.
Material And Methods: A questionnaire was used to analyze general information regarding a patient's experience of the coronavirus pandemic and, using the Inventory of Life-Changing Events, the resulting personal burden. To analyze possible associations between disease severity (EASI score, oSCORAD, IGA, PGA, POEM), quality of life (DLQI) and personal burden, t-tests, analyses of variance and correlations were evaluated, controlled for sex and age.
Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany.
J Eur Acad Dermatol Venereol
April 2022
Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry.
J Eur Acad Dermatol Venereol
March 2022
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a multifactorial genesis including genetic predispositions and environmental risk and trigger factors. One of the latter possibly is smoking, indicated by an increased prevalence of AD in adults and children that are actively or passively exposed to cigarette smoke.
Objectives: In this study, AD characteristics and its atopic comorbidities are compared in smoking and non-smoking AD patients.
Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food.
J Allergy Clin Immunol Pract
July 2021
Background: Wheat is one of the most commonly consumed foods and a known elicitor of anaphylaxis in children and adults. Reactions in adults are often cofactor dependent and characterized by a prolonged time between food intake and the onset of symptoms making the diagnosis of wheat anaphylaxis challenging.
Objective: To characterize a cohort of patients with the history of wheat anaphylaxis to better understand this atypical phenotype of anaphylaxis.
Background: Chronic urticaria (CU) is a common disease which represents a considerable burden for many patients. The current urticaria guideline describes the evidence-based diagnosis and treatment of CU. In addition, however, questions often arise in everyday practice that are not addressed by the guideline.
View Article and Find Full Text PDF